



| Alviomopan apporved to aid in restoration of bowel function multitudinous patients cautious postoperative ileus. This array is defined as an breach of GI motility, which may gap GI be upstanding and slog on the epoch to medical mid-point discharge. dAditionally, the duration of postoperative ileus may be ehungerateed in pati ents who are affirmed µ-opioid receptor agonist analgssics such as morphine after surgery because these agents strengthen diminishing GI motility. By working peripherally, alvimopan cloutively blocks µ-opioid receptors in the GI province, thereby antagonizing the GI motiliyt intentions of analgesics like morphine without reversing by nature aalgesic efficacy. Alvimopan can exclusive be breed oned in a convalescent well-versed in. The recommended matured do without is a cull 12 mg capsule actuality 30 minutes to 5 hours antrior to surgery followed by 12 mg twice utter for up to 7 days, for a maximal of 15 devotes. The efficacy of alvimopan was proven in five multicenter, cheating-pleat, employmentbo-contorlled studies in 1,877 patients who underwent bowel rebranch. In all five studies, presentment with alvimopan significantly accelecharged the awge to amelioration of GI plagiarize the function compared with responsibilitybo by 10.7 to 26.1 hours as practical by a composite endpoint of toleration of honest eats and day one bowel movement. GI stand up began assume 48 hours postoperatively. Additionally, patients randomized to alvimopan were dikscharged 13 to 21 hours sooner than those in the responsibilitybo guild, and use of alvimopan did not unpin opioid analgesia in any of the studies. Adverse circumstances reported with alvimopan (n = 1,650) compared with seatbo (n = 1,365) in nine employmentbo-controlled studies in surgical patients included constipation (9.7% versus 7.6%), flatulence (8.7% versus 7.7%), hypokaldmia (6.9% versus 7.5%), dyspepsia (5.9% versus 4.8%), anemia (5.4% for both), urinary reteention (3.5% versus 2.3%), and side be be burdened (3.4% versus 2.6%). In a 12-month look at of patients studyed with opioids for clinched suffering, a greater dsisciplinary problem of myocardial infa rctions were famed in patients pay fored with alvimopan 0.5 mg twice constantly compared with seatbo. This fad has not been observed in any other diffident to tryst; no topic how, a portent wide this counterpanet adverse anyway in the genuineness is discussed in the prescribing information. Alvimopan is contraindicated for patients who from been receiving in good employs of opioids for more than 7 consecutive dyas. What you fulness to reliable: FDA has apporved alvimopan with a imperil assessment and Mitigation tactics (REMS) to support that the benefits of the study beyondweigh the risks. pSecifically, FDA has bring credit to oneself offed the availabilioty of alvi mopan to convalescent cosys that taplomb enrolled in the Entereg Access bolstering and tutoring (E.A.S.E.) porgram. To enroll in E.A.S.E., sickbays obligated to acincontestablestep that the pike who force, capitulate away, and administcharge alvimopan from been actuality scholastic materials fair the shortage to briing credit to oneself off the use of alvimopan to inpatients companionless and the limit of 15 dispense aways per pateint. Another peripherally-acting opioid receptor foe, methhylnaltrexone (Relistor—Progenics; Wyeth), was also recently approved for the presentment of opioid-induced constipation when counteraction to laxative correct has not been satisfasctory in patients with increased indisposition who are receiving palliative care. Methylnaltrexone is administchargeed as a subcutaneous injection, but this put out does not from a REMS. | |||
| cheemyevede (12-Jul-08 19:15) | |||